Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (CPVT)

Inclusion Criteria: Males or Females ≥18 years of age, at screening. Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at screening. Ability to perform an Exercise Stress Test (EST) during which exercise-induced ventricular couplets or higher-grade VA (equivalent to a VA score ≥3) are identified by the investigator. Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to screening. Adhere to all contraceptive criteria. Exclusion Criteria: Clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease. History of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of screening. History of malignancy within the past 5 years at screening (except successfully treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ). Female participant that is pregnant or lactating/ breastfeeding, or has plans to do so during the study or within 3 months following last dose of study drug. Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.